利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

61 条记录 (耗时 0.056 秒)

    Anti-Inflammatory Proteins and Improved Vaccines
    7.
    发明申请
    Anti-Inflammatory Proteins and Improved Vaccines 审中-公开
    抗炎蛋白和改进疫苗

    公开(公告)号：US20090110694A1

    公开(公告)日：2009-04-30

    申请号：US12225456

    申请日：2007-03-22

    申请人： Geoffrey Smith ,  An-Jung Chen

    发明人： Geoffrey Smith ,  An-Jung Chen

    IPC分类号： A61K39/12 ,  C12N7/00 ,  C12N15/11 ,  C07K2/00 ,  A61K38/02 ,  A61K31/7088 ,  C12N5/06

    CPC分类号： C12N15/86 ,  A61K39/00 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/24122 ,  C12N2710/24143 ,  C12N2710/24161 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/476 ,  Y02A50/487

    摘要： A recombinant poxvirus lacking a functional gene corresponding to BI4R in the WR strain of VACV for use as a medicament especially as a vaccine against a disease caused by a poxvirus or another pathogenic agent or for use as a medicament against a disease associated with aberrant cells. An isolated nucleotide or polypeptide encoding a poxvirus sequence corresponding to the sequence of B14 in the WR strain of VACV especially for use as a medicament against undesirable inflammation, immune activation or NF-κB activation. Related compositions and methods.

    摘要翻译： 在VACV的WR菌株中缺乏与BI4R相对应的功能基因的重组痘病毒用作药物，特别是作为针对由痘病毒或另一病原体引起的疾病的疫苗或用作抗异常细胞相关疾病的药物。 编码对应于VACV的WR菌株中的B14序列的痘病毒序列的分离的核苷酸或多肽，特别是用作抗不需要的炎症，免疫激活或NF-κB活化的药物。 相关的组合物和方法。

    MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES
    8.
    发明申请
    MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES 有权
    改良的VACCINIA VIRUS ANKARA用于接种新生儿

    公开(公告)号：US20090104224A1

    公开(公告)日：2009-04-23

    申请号：US12118841

    申请日：2008-05-12

    申请人： Mathias Ackermann ,  Mark Suter ,  Hans Peter Hefti ,  Marco Franchini ,  Sabine Vollstedt ,  Paul Chaplin

    发明人： Mathias Ackermann ,  Mark Suter ,  Hans Peter Hefti ,  Marco Franchini ,  Sabine Vollstedt ,  Paul Chaplin

    IPC分类号： A61K35/76 ,  A61P37/04

    CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5254 ,  A61K2039/55 ,  A61K2039/58 ,  C12N7/00 ,  C12N2710/16634 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2710/24161 ,  Y02A50/386 ,  Y02A50/39 ,  Y02A50/394

    摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.In particular, the invention concerns the vaccination of neonates against infections with viruses belonging to the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.

    摘要翻译： 本发明涉及病毒用于制备用于疫苗接种或治疗新生儿或产前动物（包括人）的药物，其中病毒能感染新生儿或产前动物（包括人）的细胞， 但不能在新生儿或产前动物（包括人）中复制感染性后代病毒。 病毒优选为修饰的痘苗病毒安卡拉。 特别地，本发明涉及新生儿针对与用于接种疫苗的病毒相同的病毒组的病毒感染的疫苗接种。 此外，本发明涉及新生儿针对选自外源抗原和肿瘤抗原的抗原的疫苗接种，其中肿瘤抗原和/或外源抗原不同于与病毒相关的抗原。 本发明还涉及如上定义的病毒的使用以增加激活树突状细胞或其前体细胞的因子水平和/或增加树突状细胞或其前体细胞的数量和/或增加生产和/或细胞 干扰素（IFN）或IL-12的含量。